Imperial College London
Alternate

Professor the Lord Darzi of Denham PC KBE FRS FMedSci HonFREng

Faculty of Medicine, Department of Surgery & Cancer

Co-Director of the IGHI, Professor of Surgery
 
 
 
//

Contact

 

+44 (0)20 3312 1310a.darzi

 
 
//

Location

 

Queen Elizabeth the Queen Mother Wing (QEQM)St Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Erridge:2018:10.1007/s11695-018-3246-4,
author = {Erridge, S and Moussa, O and Ziprin, P and Purkayastha, S},
doi = {10.1007/s11695-018-3246-4},
journal = {Obesity Surgery},
pages = {1--8},
title = {Risk of GERD-related disorders in obese patients on PPI therapy: a population analysis},
url = {http://dx.doi.org/10.1007/s11695-018-3246-4},
volume = {105},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundIncreasing prevalence of obesity has shown an associated increase in gastroesophageal reflux disease (GERD)-related diseases. Proton pump inhibitor (PPI) therapy has been demonstrated to reduce the incidence of such diseases. The study’s aim was to analyze the Clinical Practice Research Datalink (CPRD) to determine factors that increase the propensity of obese patients on PPIs to develop Barrett’s esophagus (BE) and esophageal carcinoma.MethodA case-control population study was carried out, including patients from the CPRD. Clinicopathological factors were extracted for each patient alongside clinical endpoints of GERD, BE, and esophageal carcinoma. Multivariate analysis was utilized to identify factors that increase the propensity to develop BE and esophageal carcinoma. Statistical significance was p < 0.050.ResultsOne hundred sixty five thousand nine hundred twenty nine obese patients on PPI treatment were identified up until July 2017. Median follow-up time was 119.0 months (range 11.3–1397.9 months). In patients with GERD, the following were associated with increased BE risk: age ≥ 60 years (OR = 1.197; p = 0.039), male (OR = 2.209; p < 0.001), H2 antagonists (OR = 1.377; p < 0.001), D2 antagonists (OR = 1.241; p = 0.008), and hiatus hernias (OR = 6.772; p = 0.017). The following were associated with increased risk of esophageal carcinoma: age (OR = 2.831; p = 0.031), male sex (OR = 3.954; p = 0.003), and hiatus hernias (OR = 12.170; p < 0.001). Only D2 antagonists (OR = 2.588; p = 0.002) were associated with increased risk of developing esophageal carcinoma in BE patients.ConclusionsIn obese patients on PPI therapy for reflux, higher BMIs were not associated with increased risk of BE or esophageal carcinoma. Male
AU  - Erridge,S
AU  - Moussa,O
AU  - Ziprin,P
AU  - Purkayastha,S
DO  - 10.1007/s11695-018-3246-4
EP  - 8
PY  - 2018///
SN  - 0960-8923
SP  - 1
TI  - Risk of GERD-related disorders in obese patients on PPI therapy: a population analysis
T2  - Obesity Surgery
UR  - http://dx.doi.org/10.1007/s11695-018-3246-4
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000426843500041&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/60798
VL  - 105
ER  -
Download